TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BioNTech SE ( (BNTX) ) has provided an announcement.
On November 26, 2025, BioNTech SE announced the approval of its exchange offer for all outstanding shares of CureVac N.V., following an extraordinary general meeting held by CureVac on November 25, 2025. The offer, which expires on December 3, 2025, involves an exchange ratio of 0.05363 BioNTech ADS per CureVac share. The transaction aims to strengthen BioNTech’s market position by acquiring at least 80% of CureVac’s shares, with a potential reduction to 75% if conditions are met. This strategic move is expected to enhance BioNTech’s capabilities in the biopharmaceutical industry, benefiting stakeholders by expanding its portfolio and market reach.
The most recent analyst rating on (BNTX) stock is a Buy with a $150.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.
Spark’s Take on BNTX Stock
According to Spark, TipRanks’ AI Analyst, BNTX is a Neutral.
BioNTech’s overall stock score reflects a challenging financial performance with recent losses, offset by a strong balance sheet and strategic advancements in oncology. Technical indicators suggest a neutral trend, while valuation remains unattractive due to negative earnings. The earnings call provided positive guidance, but regulatory delays and financial losses remain concerns.
To see Spark’s full report on BNTX stock, click here.
More about BioNTech SE
Biopharmaceutical New Technologies (BioNTech) is a global next-generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. The company leverages computational discovery and therapeutic modalities to rapidly develop novel biopharmaceuticals. BioNTech’s diverse oncology product candidates include mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies such as antibody-drug conjugates and chimeric antigen receptor T cell therapies. Additionally, BioNTech is developing multiple mRNA vaccine candidates for infectious diseases and has partnerships with various global pharmaceutical companies.
Average Trading Volume: 941,471
Technical Sentiment Signal: Sell
Current Market Cap: $23.98B
See more data about BNTX stock on TipRanks’ Stock Analysis page.